Tetranor PGDM analyses for the amyotrophic lateral sclerosis: positive and simple diagnosis and evaluation of drug effect.
Amyotrophic lateral sclerosis (ALS) is a late-onset, progressive motor neuronal degenerative disease occurring as sporadically and as a familial disorder. The patients with ALS typically become progressively paralyzed and develop respiratory failure that eventually leads to death within 3-5years. For this disease, there is no effective diagnostic method and also drug. This report describes a simple and useful diagnostic biomarker for ALS. Our findings suggest that the combination analysis of a metabolite of prostaglandin D2, 11,15-dioxo-9-hydroxy-,2,3,4,5-tetranorprostan-1,20-dioic acid (tetranor PGDM and tPGDM) with creatinine is the diagnostic approach for ALS with high accuracy. tPGDM has the potential to be an important diagnostic tool in the pre-symptomatic stages and progression evaluation of ALS, and also to be a biomarker for the evaluation of drug effect.
Environmental Biotechnology Institute, 447-27 Kakinuma, Kumagaya, Saitama 360-0803, Japan. takaoshinozawa@hotmail.com
Takao
T
Shinozawa
Yoshihiro
Y
Urade
Toshihiko
T
Maruyama
Daishi
D
Watabe
D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000652:urine; D015415:Biomarkers / Q000652:urine; D054316:Biomarkers, Pharmacological / Q000652:urine*; D003401:Creatine / Q000652:urine; D006801:Humans; D008297:Male; D008875:Middle Aged; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000652:urine; D016482:Urinalysis / Q000379:methods*
C527346:11,15-dioxo-9-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid; D015415:Biomarkers; D054316:Biomarkers, Pharmacological; D003401:Creatine; D015230:Prostaglandin D2